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Abstract Background hospitalized patients with serious
infections treated with aminoglycosides are at risk of
developing nephrotoxicity. Previous clinical studies have
shown that the pharmacokinetics of aminoglycosides in
humans follow a circadian rhythm. Therefore, the time of
administration could have important clinical implications
with respect to the risk of developing aminoglycoside-
associated nephrotoxicity in patients treated with once daily
dosing regimens. Objective To examine the effect of the time
period of administration on aminoglycoside exposure and
the incidence of nephrotoxicity in a large population of
hospitalized patients with serious infections. Setting General
ward and intensive care unit of a teaching hospital. Method In
this retrospective cohort study, patients treated with intra-
venous tobramycin or gentamicin were eligible for inclusion.
Patients were divided into three groups by time of adminis-
tration: morning, afternoon and night. Main outcome mea-
sure Pharmacokinetic parameters and the incidences of
nephrotoxicity were compared between the morning, after-
noon and evening groups. Results 310 general ward and 411
intensive care unit patients were included. No significant
differences were found in patient characteristics between the
morning, afternoon and night groups. The time period of
administration did not affect aminoglycoside pharmacoki-
netics or the incidence of nephrotoxicity. Conclusion The
time of administration has no effect on the pharmacokinetics
or nephrotoxicity of once daily dosed aminoglycosides in
hospitalized patients. Consequently, we advise aminogly-
cosides to be administered as soon as possible in case of
(suspected) severe hospital-acquired infections and sub-
sequent dosages to be based on therapeutic drug monitoring
to optimize the efficacy/toxicity balance.
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Impacts on practice
• There is no effect of the diurnal rhythm on aminogly-
coside pharmacokinetics hospitalized clinically infec-
ted patients.
• Administration of aminoglycosides during the night-
time (21:00–5:00) compared to the daytime
(5:00–21:00) does not increase the risk of nephrotox-
icity in hospitalized patients with serious infections.
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• Shifting administrations of aminoglycosides from
nighttime to daytime most likely does not offer any
benefit to hospitalized patients with serious infections.
Introduction
Aminoglycoside antibiotics remain an important group of
antimicrobial agents in the treatment of serious infections by
gram-negative organisms [1]. Although they are highly
effective at killing these organisms, exposure to intravenous
aminoglycosides comes with an increased risk of auditory and
renal toxicity [2]. All hospitalized patients, especially criti-
cally ill patients with a low renal clearance of aminoglyco-
sides, are at high risk of developing nephrotoxicity [3, 4]. In an
attempt to reduce the nephrotoxic side effects without com-
promising efficacy, once-daily dosing regimens of amino-
glycosides have shown to be superior to conventional multiple
daily dosing regimens [5]. Nowadays, intravenous amino-
glycosides are primarily dosed once daily [6]. Since a circa-
dian rhythm of aminoglycoside pharmacokinetics has been
observed in animal experiments [7–10] as well as in human
studies involving multiple daily dosing protocols [11, 12], the
clearance of aminoglycosides is expected to be higher during
daytime compared to nighttime due to a higher glomerular
filtration rate in the ‘active period’. As a result, the time of
administration in patients receiving their drug with 24-h
intervals could have important implications with respect to
aminoglycoside clearance. Nevertheless, human data on the
effect of the circadian rhythm on the pharmacokinetics and
toxicity of once daily dosed aminoglycosides are inconsistent
[13, 14]. To date, the effect of diurnal changes on aminogly-
coside pharmacokinetics has not been extensively studied in a
large cohort of patients with serious infections.
Aim of the study
To examine the effect of time period of administration on
aminoglycoside pharmacokinetics and the incidence of
nephrotoxicity in a large population of hospitalized clini-
cally infected patients.
Ethical approval
A waiver for consent was provided by the local medical
ethics committee.
Method
In this retrospective cohort study data were extracted from
patients’ clinical records and a therapeutic drug monitoring
database. All general ward and intensive care unit patients
of 18 years or older who were admitted to hospital between
January 2006 and December 2013 and were treated with
intravenous tobramycin or gentamicin were eligible for
inclusion. Furthermore, an estimated glomerular filtration
rate calculated with the MDRD formula [15] higher than
25 mL/min and a once daily dose of 4–6 mg/kg were
required. Finally, two aminoglycoside serum concentra-
tions drawn after the first or second infusion were man-
datory for inclusion. For the analysis of nephrotoxicity in
the general ward population, the treatment duration had to
be 2 days or longer. Furthermore, a minimum of two serum
creatinine concentrations was required; one drawn between
48 h before and 12 h after initiation of therapy. If two or
more concentrations were available in this time frame the
concentration drawn closest to the time of intiation of
aminoglycoside therapy was selected as the baseline cre-
atinine concentration. A second ‘post-treatment’ concen-
tration drawn between 48 h after initiation and 48 h after
cessation of therapy was mandatory for inclusion. If two
‘post-treatment’ concentrations were available in this per-
iod the highest creatinine concentration was appointed as
the ‘post-treatment’ concentration. The delta serum creat-
inine (DScr) was defined by the ‘post-treatment’ change in
creatinine serum concentration from baseline. Nephrotox-
icity was defined as a minimal DScr of 45 nmol/mL
(0.5 mg/dL) [14]. According to the therapeutic drug mon-
itoring (TDM) protocol, a peak concentration and second
concentration were drawn 0.5–1 and 6–14 h after end of
the first or second infusion, respectively. The target peak
concentration was 15–20 mg/L, and the target trough
concentration was \0.5 mg/L. It was a priori decided to
analyze the pharmacokinetics separately for general ward
and intensive care unit populations and to analyze the
incidence of nephrotoxicity only in the general ward pop-
ulation, because the kidney function of the latter population
has an inherently large variability and many artifacts occur
due to cardiovascular management. Patients were divided
into three groups by time of administration: 5:00–12:55
(morning), 13:00–20:55 (afternoon) and 21:00–4:55
(night). Pharmacokinetic parameters were calculated for
each individual patient using pharmacokinetic software
(MW\Pharm 3.80, MediWare, Zuidhoorn, The Nether-
lands) and a population pharmacokinetic model.
Statistical analyses
A Kolmogorov–Smirnov test was used to test normal dis-
tribution of the data. Means and standard deviations of
continuous variables are presented in case of normal dis-
tribution. Otherwise, medians and ranges were reported.
One-way ANOVA with Bonferroni post hoc tests were
used to determine statistical differences among normal data
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distributions. If the data were not normally distributed, a
Kruskal–Wallis non-parametric method was applied with
Mann–Whitney-U post hoc tests including correction for
multiple testing. A Chi square test was used to compare
dichotomous variables between groups. All statistical
analyses were performed using GraphPad Prism version
5.03 for Windows (GraphPad Software, San Diego, CA,
USA). A p value of\0.05 was considered to be statistically
significant and in each instance a two-sided test was carried
out.
Results
A total of 1,452 general ward and 843 intensive care unit
patients were selected from the TDM database. Approxi-
mately half of the selected general ward and intensive care
unit patients were excluded as a result of missing phar-
macokinetic data. In the general ward population, subse-
quently again half of the remaining patients were excluded
from the nephrotoxicity analysis because of missing cre-
atinine values or a treatment duration shorter than 2 days.
In total 310 general ward and 411 intensive care unit
patients were eligible for inclusion in the morning, after-
noon and night groups. No significant differences were
found in patient characteristics between the three groups in
both populations (Table 1).
Although a trend toward a higher volume of distribution
in the afternoon group was seen in the general ward pop-
ulation compared to the morning or night groups (0.28,
0.25 and 0.24 L/kg respectively, p = 0.06), aminoglyco-
side clearance and area-under-the-curve (AUC) did not
differ significantly between the morning, afternoon and
night groups in both populations (Table 2).
Finally, no significant differences in DScr (p = 0.11) or
in percentages of patients developing nephrotoxicity
(p = 0.47) were found between the morning, afternoon and
night groups of the general ward population (Table 2).
Discussion
This large retrospective study found no differences in
aminoglycoside exposure or nephrotoxicity related to time
of administration in hospitalized patients with serious
infections. Caution needs to be exercised when interpreting
the results of any retrospective cohort study because of
errors due to confounding and inclusion bias. However,
baseline characteristics showed no significant differences
between groups and the proportion of excluded patients per
exclusion criterion did not differ significantly between
patients who were administered aminoglycosides in the
morning, afternoon and night.
Since most previous studies did find an effect of the cir-
cadian rhythm on the pharmacokinetics of aminoglycosides,
our results intuitively seem unexpected. Nevertheless, an in-
depth review of the available evidence demonstrates that the
animal and preclinical studies were performed in relatively
small populations of animals or (young) healthy volunteers,
primarily investigated multiple daily or even continuously
dosed aminoglycoside dosing regimens, had suboptimal
pharmacokinetic sampling protocols with only peak and
trough concentration monitoring and/or reported on amika-
cin and kanamycin that are more likely to accumulate [7–12,
16–18]. In addition and perhaps most eminent, TDM in the
majority of these studies was performed after 3 days of
therapy. At that moment in time a large proportion of patients
will no longer show signs of an infection and aminoglyco-
sides are withdrawn in current clinical practice. It is thus
critical to collect pharmacokinetic data during the first
2 days of therapy when the patient is still showing signs of an
ongoing infection, since sepsis and an altered status of the
immune system disrupt the circadian rhythm [19, 20]. Our
study investigated a large population of hospitalized patients
with serious infections, who received their aminoglycosides
once daily with optimal pharmacokinetic sampling during
the first or the second administration.
The results from human studies examining the effect of
the circadian rhythm on the pharmacokinetics of amino-
glycosides are conflicting [14, 21–24]. The three ‘positive’
studies all involved multiple daily dosing protocols of
‘earlier’, and more accumulating aminoglycosides (e.g.
kanamycin and amikacin). In contrast, the two ‘negative’
studies reported on once or twice daily dosed aminoglyco-
sides that show relatively low tissue accumulation (e.g.
tobramycin, netelmicin and gentamicin). A randomized
controlled trial by Fauvelle et al. [23], in which netilmicin
(4.5 mg/kg of lean body weight) was administered every
24 h at 10 a.m. or 10 p.m. to 23 ill febrile patients with
severe infection, showed that the time of administration had
no influence on netilmicin concentrations in serum nor on
pharmacokinetic parameters in these patients. The second
was a prospective cohort study by Prins et al. [14] who
investigated the influence of the time of drug administration
on serum drug concentrations and the incidence of neph-
rotoxicity in 179 patients with serious infections treated
with gentamicin or tobramycin once daily. This study found
no statistically significant differences in trough or peak
concentrations for three time periods of administration.
Nevertheless, the incidence of nephrotoxicity was signifi-
cantly higher when the aminoglycosides were administered
during the nighttime (midnight to 7:30 AM; p = 0.004) to a
combined general ward and intensive care unit population.
In our opinion, data on pharmacokinetics and nephrotoxi-
city of aminoglycosides in general ward and intensive care
unit populations should be analyzed separately since
344 Int J Clin Pharm (2015) 37:342–347
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admission to the intensive care unit is a known risk factor
for acute kidney injury [25, 26]. Moreover, the study by
Prins et al. [14] demonstrated that intensive care unit
patients are more ‘at risk’ to receive their aminoglycosides
during the night (77 vs. 44 %). Admission to the intensive
care unit is thereby a confounder by definition, since it
correlates with both the dependent (i.e. nephrotoxicity) and
the independent variable (i.e. time of administration). Fur-
thermore, the authors had to statistically correct for not only
the higher intensive care unit admissions but also for sig-
nificantly poorer baseline creatinine clearance (84 vs.
100 mL/min, p \ 0.05) in the nighttime compared to day-
time group. All of the above are established risk factors of
acute kidney injury [25, 26]. Altogether, it is debatable
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c Chi square test
General ward Time of administration
Morning (n = 88) Afternoon (n = 108) Night (n = 114) p value
Age (years) 63 ± 34 62 ± 27 57 ± 31 0.56a
Weight (kg) 70 ± 29 71 ± 27 70 ± 26 0.33a
% of males 42 48 56 0.10c
% of patients on TOB 21 27 19 0.23c
eGFR (ml/min) 80 (26–191) 88 (26–189) 89 (26–185) 0.27b
Nephrotoxic comedication 0.26c
Furosemide (%) 2.5 3.1 2.9
Vancomycin (%) 1.1 1.2 3.1
Ward 0.42c
Surgical (%) 39 40 34
Internal (%) 53 51 49
Pulmonary diseases (%) 6 7 12
Other (%) 3 2 4
Intensive care unit Morning (n = 124) Afternoon (n = 145) Night (n = 142) p value
Age (years) 68 ± 32 65 ± 28 68 ± 31 0.14a
Weight (kg) 72 ± 28 75 ± 26 75 ± 24 0.48a
% of males 64 65 69 0.47c
% of patients on TOB 48 43 39 0.35c
eGFR (ml/min) 55 (25–167) 64 (25–183) 57 (25–167) 0.41b
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medians with ranges in
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Abbreviations are: AUC area
under the concentration time
curve, CL clearance, Scr serum
creatinine, Vd volume of




c Chi square test
General ward Time of administration
Morning (n = 88) Afternoon (n = 108) Night (n = 114) p value
Dose (mg) 350 (180–500) 360 (220–600) 350 (240–650) 0.48b
Treatment duration (days) 5 (3–18) 5 (3–22) 5 (3–21) 0.98b
CL (L/h) 4.4 ± 1.7 4.6 ± 1.8 4.7 ± 1.7 0.41a
Vd (L/kg) 0.25 ± 0.08 0.28 ± 0.09 0.24 ± 0.08 0.06a
AUC (mg h/L) 135 ± 47 139 ± 48 145 ± 51 0.97a
DScr (nmol/mL) 6 (-40–167) 0 (-11–323) -1 (-56–467) 0.11b
Nephrotoxicity (%) 18 12 10 0.47c
ICU Morning (n = 124) Afternoon (n = 145) Night (n = 142) p value
Dose (mg) 350 (250–675) 360 (240–600) 360 (150–750) 0.36b
Treatment duration (days) 4 (3–12) 4 (3–13) 5 (3–17) 0.72b
CL (L/h) 1.9 ± 0.06 2.1 ± 0.08 2.1 ± 0.07 0.19a
Vd (L/kg) 0.33 ± 0.11 0.32 ± 0.10 0.33 ± 0.12 0.85a
AUC (mg h/L) 195 ± 71 183 ± 75 173 ± 67 0.86a
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whether statistical correction is a proper tool to adjust for
these imbalances in patient characteristics.
Our data show a trend of a higher volume of distribution
in the afternoon group of the general ward population but
not in the intensive care unit population. This is most likely
caused by the discrepancy in the daily fluid management of
a general ward patient compared to an intensive care unit
patient. Whereas the latter will receive intravenous fluids
continuously, contributing to a relatively stable volume of
distribution throughout the day, a general ward patient will
gain fluids during the day causing the volume of distribu-
tion of hydrophilic aminoglycosides to peak in the
afternoon.
The presented pharmacokinetic data are in accordance
with the data reported by Fauvelle et al. [23] and are further
supported by the unpublished results of two randomized
clinical trials in adult and pediatric cystic fibrosis patients
suffering from pulmonary exacerbation. Both studies found
no effect of the circadian rhythm on the pharmacokinetics
of once daily dosed tobramycin in cystic fibrosis patients
(submitted for publication).
Conclusion
Currently, it is widely believed that administration of
aminoglycosides in the morning will result in a reduction in
nephrotoxicity and many (international) antibiotic guide-
lines advise administration of aminoglycosides in the
morning. This large retrospective study, however, shows
no administration-time-related differences in aminoglyco-
side exposure or nephrotoxicity in hospitalized clinically
infected patients. It is therefore unlikely that administration
during the nighttime will result in a higher incidence of
renal toxicity in these patients. We recommend amino-
glycosides to be administered as soon as possible in case of
(suspected) severe hospital-acquired pneumonia or sepsis
to reduce the pen-to-needle time in antibiotics, which has
shown to be effective in preventing death [27]. Subsequent
doses should be based on therapeutic drug monitoring to
optimize the efficacy/toxicity balance.
Acknowledgments We would like to thank W. Abdelhadi, PharmD,
from the Faculty of Pharmacy, University of Utrecht, The Netherlands
for her help with data collection and analysis.
Funding No funding was received for this study.
Conflicts of interest The authors declare that they have no com-
peting interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux
M. Clinical and bacteriological efficacy, and practical aspects of
amikacin given once daily for severe infections. J Antimicrob
Chemother. 1991;27(Suppl C):91–103.
2. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of
studies on the safety and efficacy of aminoglycosides given either
once daily or as divided doses. J Antimicrob Chemother.
1996;37:645–63.
3. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA.
Experience with a once-daily dosing program of aminoglycosides
in critically ill patients. Intensive Care Med. 2002;28(7):936–42.
4. Hansen M, Christrup LL, Jarlov JO, Kampmann JP, Bonde J.
Gentamicin dosing in critically ill patients. Acta Anaesthesiol
Scand. 2001;45(6):734–40.
5. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in
immunocompetent adults: a meta-analysis. Ann Intern Med.
1996;124(8):717–25.
6. Bodmann KF. Current guidelines for the treatment of severe
pneumonia and sepsis. Chemotherapy. 2005;51(5):227–33.
7. Hosokawa H, Nyu S, Nakamura K, Mifune K, Nakano S. Cir-
cadian variation in amikacin clearance and its effects on efficacy
and toxicity in mice with and without immunosuppression.
Chronobiol Int. 1993;10:259–79.
8. Song J, Ohdo S, Ogawa N, Nakano S. Influence of feeding
schedule on chronopharmacological aspects of gentamicin in
mice. Chronobiol Int. 1993;10:338–48.
9. Yoshiyama Y, Kobayashi T, Tomonaga F. Chronotoxical study of
gentamicin induced nephrotoxicity in rats. J Antibiot (Tokyo).
1992;45:806–8.
10. Yoshiyama Y, Nishikawa S, Sugiyama T, Kobayashi T, Shimada
H, Tomonaga F, et al. Influence of circadian-stage-dependent
dosing schedule on nephrotoxicity and pharmacokinetics of isep-
amicin in rats. Antimicrob Agents Chemother. 1993;37:2042–3.
11. Dickson CJ, Schwartzman MS, Bertino JS. Factors affecting
aminoglycoside disposition: effects of circadian rhythm and
dietary protein intake on gentamicin pharmacokinetics. Clin
Pharmacol Ther. 1986;39:325–8.
12. Yoshiyama Y, Grenier L, Gourde P, Simard M, Lin L, Morin NJ.
Temporal variation in nephrotoxicity of low doses of isepamicin
in rats. Antimicrob Agents Chemother. 1996;40:802–6.
13. Beauchamp D, Labrecque G. Chronobiology and chronotoxicol-
ogy of antibiotics and aminoglycosides. Adv Drug Deliv Rev.
2007;59(9–10):896–903.
14. Prins JM, Weverling GJ, van Ketel RJ, Speelman P. Circadian
variations in serum levels and the renal toxicity of aminoglyco-
sides in patients. Clin Pharmacol Ther. 1997;62:106–11.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A
more accurate method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation. Modification of Diet
in Renal Disease Study Group. Ann Intern Med. 1999;130(6):
461–70.
16. Fauconneau B, De Lemos E, Pariat C, Bouquet S, Courtois P,
Piriou A. Chronotoxicity in rat of a vancomycin and gentamicin
combination. Pharmacol Toxicol. 1992;71:31–6.
17. Lin L, Grenier L, Bergeron Y, Simard M, Bergeron MG, Lab-
recque G, et al. Temporal changes of pharmacokinetics, neph-
rotoxicity, and subcellular distribution of tobramycin in rats.
Antimicrob Agents Chemother. 1994;38(1):54–60.
18. Pariat C, Courtois P, Cambar J, Piriou A, Bouquet S. Circadian
variations in the renal toxicity of gentamicin in rats. Toxicol Lett.
1988;40:175–82.
19. Verceles AC, Silhan L, Terrin M, Netzer G, Shanholtz C, Scharf
SM. Circadian rhythm disruption in severe sepsis: the effect of
346 Int J Clin Pharm (2015) 37:342–347
123
ambient light on urinary 6-sulfatoxymelatonin secretion. Inten-
sive Care Med. 2012;38(5):804–10.
20. Habbal OA, Al-Jabri AA. Circadian rhythm and the immune
respons: a review. Int Rev Immunol. 2009;28:93–108.
21. Bleyzac N, Allard-Latour B, Laffont A, Mouret J, Jelliffe R,
Maire P. Diurnal changes in the pharmacokinetic behavior of
amikacin. Ther Drug Monit. 2000;22:307–12.
22. Elting L, Bodey GP, Rosenbaum B, Fainstein V. Circadian var-
iation in serum amikacin levels. J Clin Pharmacol.
1990;30:798–801.
23. Fauvelle F, Perrin P, Belfayol L, Boukari M, Cherrier P, Bosio
AM, et al. Fever and associated changes in glomerular filtration
rate erase anticipated diurnal variations in aminoglycoside phar-
macokinetics. Antimicrob Agents Chemother. 1994;38:620–3.
24. Lucht F, Tigaud S, Esposito G, Cougnard J, Fargier MP, Peyra-
mond D, et al. Chronokinetic study of netilmicin in man. Eur J
Clin Pharmacol. 1990;39:199–201.
25. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR,
Nafziger AN. Incidence of and significant risk factors for ami-
noglycoside-associated nephrotoxicity in patients dosed by using
individualized pharmacokinetic monitoring. J Infect Dis.
1993;167(1):173–9.
26. Zappitelli M, Parikh CR, Akcan-Arikan A, Washburn KK,
Moffett BS, Goldstein SL. Ascertainment and epidemiology of
acute kidney injury varies with definition interpretation. Clin J
Am Soc Nephrol. 2008;3(4):948–54.
27. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S,
et al. Duration of hypotension before initiation of effective
antimicrobial therapy is the critical determinant of survival in
human septic shock. Crit Care Med. 2006;34(6):1589–96.
Int J Clin Pharm (2015) 37:342–347 347
123
